Illumina (ILMN) Following Novacyt Deal Has Investors Asking If The Stock Looks Fully Valued
Illumina (ILMN) has drawn fresh investor attention after Novacyt S.A. entered a five year Master Collaboration Agreement with the genomics group, establishing a framework for potential future product and commercial projects.
Recent price action backs up this flurry of announcements around Illumina. The share price has climbed 12.29% over the past month and 29.91% across 90 days, contributing to a 57.10% year to date share price return. The 1 year total shareholder return of 114.88% highlights how quickly sentiment has shifted, despite a 5 year total shareholder return that remains down 51.61%, which points to momentum rebuilding from a still damaged longer term track record.
See how Illumina’s momentum compares with other potential turnaround stories by filtering for 17 high quality undiscovered gems, which screens for fundamentals rather than just headlines.
After a 114.88% 1-year total return and a move that has pushed Illumina to US$211.06, the tension is simple: Do you step in after this rebound or wait for the valuation section to flag a cleaner entry point?
Most Popular Narrative: 5.7% Overvalued
Illumina's most followed valuation storyline pegs fair value at $199.63, which sits below the last close of $211.06, so the market is pricing in a premium to that framework.
Strong and resilient growth in clinical applications especially oncology, genetic disease testing, and reproductive health continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility.
Curious what has to happen in Illumina's clinical and multiomics push to support that fair value, including its margin profile and earnings power over time. The narrative hinges on specific growth, profitability and valuation assumptions that go well beyond the recent share price move. The detail sits in how those moving parts are expected to compound together.
Result: Fair Value of $199.63 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Illumina’s reliance on clinical demand and ongoing legal exposure in markets like Germany could quickly undermine the positive outlook for margins and earnings.
Find out about the key risks to this Illumina narrative.
Another View: Illumina Through The Cash Flow Lens
The earlier narrative frames Illumina as 5.7% overvalued relative to a US$199.63 analyst fair value, yet our DCF model points in the opposite direction. On that measure, Illumina at US$211.06 trades around 18.4% below an estimated future cash flow value of US$258.53, which raises a different question. Is the market overpaying against earnings targets or underpaying for long term cash generation potential?
For anyone who wants to see how those moving parts are stitched together in practice, the SWS DCF model is laid out in full, step by step, in the background materials. Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Sentiment on Illumina is clearly split, with real enthusiasm sitting alongside clear concerns, so move quickly and review the underlying data yourself before opinions harden. To see both sides of that debate in one place, start with the 2 key rewards and 3 important warning signs.
Looking for more Illumina style investment ideas?
If Illumina has sharpened your focus on quality and timing, it makes sense to widen the lens and hunt for other stocks that fit your playbook using the Simply Wall St screener.
- Target resilient growth by filtering for companies that our process flags as 17 high quality undiscovered gems before attention fully catches up to their fundamentals.
- Strengthen your downside protection by zeroing in on businesses with robust finances through a list of solid balance sheet and fundamentals (24 results) that can better handle tough conditions.
- Lock in potential income ideas by scanning for reliable payers inside a curated 6 dividend fortresses that focuses on higher yielding opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com